Monoclonal Antibody Specific for TIRC7 Induces Donor-specific Anergy and Prevents Rejection of Cardiac Allografts in Mice

American Journal of Transplantation

Volumn 4, Issue 4, 2004, Pages 505-514

  Kumamoto, Yusuke ^a,b   Tomschegg, Antje ^b   Bennai Sanfourche, Fatima ^b   Boerner, Anke ^b   Kaser, Arthur ^c   Schmidt Knosalla, Isabella ^a   Heinemann, Thomas ^b   Schlawinsky, Mirko ^b   Blumberg, Richard S ^c   Volk, Hans Dieter ^a   Utku, Nalan ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b Genpat77 Pharmacogenetics AG   (Germany)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute rejection; Anergy; Cardiac transplantation; TIRC7; Type 1 cytokines

Indexed keywords

ALLOANTIGEN; COMPLEMENTARY DNA; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TIRC7; PROTEIN; T CELL IMMUNE RESPONSE C DNA 7; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; CLONAL ANERGY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG TARGETING; GRAFT SURVIVAL; HEART TRANSPLANTATION; HETEROTOPIC TRANSPLANTATION; IMMUNOMODULATION; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; ORGAN DONOR; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CELL MEMBRANE; DNA, COMPLEMENTARY; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-4; LYMPHOCYTES; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MYOCARDIUM; PROTEIN SUBUNITS; RECEPTORS, INTERLEUKIN-2; SPLEEN; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 11144355007     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00367.x     Document Type: Article

References (26)

1. McDiarmid SV, Busuttil RW, Ascher NL et al. FK. 506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric transplantation. Results from the U.S. multicenter trial. Transplantation 1995; 59: 530-536.
2. Platz KP, Mueller AR, Blumhardt G et al. Nephrotoxicity after orthotopic liver transplantation in cyclosporine A and FK506-related patients. Transpl Int 1994; 7 (Suppl. 1): S52-S57.
3. Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998; 338: 1813-1821.
4. Bluestone JA. New perspectives of CD28-B7-mediated T cell costimulation. Immunity 1995; 2: 555-559.
5. Thompson CB. Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell 1995; 81: 979-982.
6. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993; 11: 191-212.
7. Tan P, Anasetti C, Hansen JA et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993; 177: 165-173.
8. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998; 16: 111-135.
9. Vincent J. Biogen News (press release November 2). [www.document]. URL http://www.prnewswire.com, 1999.
10. Koglin J, Granville DJ, Glysing-Jensen T et al. Attenuated acute cardiac rejection in NOS2-/- recipients correlates with reduced apoptosis. Circulation 1998; 99: 836-842.
11. Hara M, Kingsley CI, Niimi M et al. IL-10 is required for regulatoly T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001; 166: 3789-3796.
12. Boussiotis VA, Chen ZM, Zeller JC et al. Altered T-cell receptor + CD28-mediated signaling and blocked cell cycle progression in interleukin 10 and transforming growth factor-β-treated alloreactive T cells that do not induce graft-versus-host disease. Blood 2001; 97: 565-571.
13. + regulatory cells that control intestinal inflammation. J Exp Med 2000; 192: 295-302.
14. Zheng XX, Markees TG, Hancock WW et al. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. J Immunol 1999; 162: 4983-4990.
15. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000; 192: 303-309.
16. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997; 7: 445-450.
17. Bluestone JA. Is CTLA-4 a master switch for peripheral T cell tolerance? J Immunol 1997; 158: 1989-1993.
18. Utku N, Heinemann T, Tullius SG et al. Prevention of acute allograft rejection by antibody targeting of TIRC7, novel T cell membrane protein. Immunity 1998; 9: 509-518.
19. Heinemann T, Bulwin GC, Randall J et al. Genomic organization of gene coding for TIRC7, a novel membrane protein essential for T cell activation. Genomics 1999; 57: 398-406.
20. Shulzhenko N, Morgun A, Rampim GF et al. Monitoring of intragraft and peripheral blood TIRC7 expression as a diagnostic tool for acute cardiac rejection in humans. Human Immunol 2001; 62: 342-347.
21. Corry RJ, Winn HJ, Russel PS. Primary vasculized allografts of hearts in mice: the role of H-2D, H-2K and non-H2 antigens. Transplantation 1973; 16: 343-350.
22. Köhler G, Milstein C. Continuous culture of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497.
23. Shimizu K, Schonbeck U, Mach F, Libby P, Mitchell RN. Host CD40 ligand deficiency induces lond-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis. J Immunol 2000; 165: 3506-3518.
24. Benichou G, Valujskikh A, Heeger PS. Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. J Immunol 1999; 162: 352-358.
25. Sayegh MH, Akalin E, Hancock WW et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995; 181: 1869-1874.
26. Turka LA, Linsley PS, Lin H et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992; 89: 11102-11105.